| abstract |
The present invention relates to arylpiperazine compounds of formula (I) which are effective pharmaceutical agents for the treatment of conditions related to or affected by serotonin 1A receptor. The compounds are useful for the relief of symptoms associated with nicotine or tobacco withdrawal. In the formula (I), Ar 'is a single or two-ring aryl or heteroaryl group having 1 to 3 hydrogen atoms, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 2 -C 6 alkenyl - substituted with (C 2 -C 6) alkynyl, halogenated (C 1 -C 6) -alkyl, (C 3 -C 8) -cycloalkyl, (C 3 -C 8) -cycloalkenyl or halogen; R 1 is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio; R 2 is phenyl, naphthyl or C 3 -C 12 cycloalkyl selected from 1 to 2 hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylthio, C 2 -C 6 -alkenyl, C 6 -C 6 alkynyl, halogenated, C 1 -C 6 -alkyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkenyl or halo; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 2-6 alkenyl, C 2-6 alkynyl, halogenated, C 1-6 alkyl, C 3-8 cycloalkyl - (C3-C8) cycloalkenyl or halogen; X is -C (= O) -, -CHOH- or -CH 2 -. SHE |